Dihydroberberine (Glucovantage)
Also known as: Dihydroberberine, DHB, GlucoVantage®
Overview
Dihydroberberine (DHB) is a reduced, more bioavailable form of berberine, an isoquinoline alkaloid found in plants like Berberis. As a supplement, it's primarily used to improve glycemic control and metabolic health. DHB exhibits enhanced absorption compared to berberine, leading to higher plasma concentrations at lower doses. Research indicates that DHB is converted to berberine in vivo, activating AMP-activated protein kinase (AMPK), a key regulator of glucose and lipid metabolism. While research is still emerging, initial human trials and pharmacokinetic studies show promise. It is not commonly found directly in nature but is produced via reduction of berberine. Available evidence includes randomized controlled trials (RCTs) with small sample sizes, pharmacokinetic studies, and systematic reviews/meta-analyses on berberine and related compounds. Direct, high-powered RCTs on dihydroberberine are limited but growing.
Benefits
Dihydroberberine significantly increases plasma berberine concentrations compared to equivalent or higher doses of berberine. Studies show that 100-200 mg of dihydroberberine can produce plasma berberine levels several-fold higher than 500 mg of berberine, with a substantially larger area under the curve (AUC) and peak concentration (Cmax). This enhanced bioavailability may translate into improved glycemic control markers, including reductions in blood glucose and insulin levels, although short-term supplementation may not show significant changes in healthy individuals. There is also potential for improved weight management via mechanisms linked to GLP-1 modulation, as suggested by meta-analyses on berberine and supported by emerging preclinical data on dihydroberberine. Most evidence focuses on overweight or glucose-intolerant populations, with preliminary data suggesting better absorption and metabolic effects in these groups.
How it works
Dihydroberberine is converted to berberine in vivo, which activates AMP-activated protein kinase (AMPK), a key regulator of glucose and lipid metabolism. It improves insulin sensitivity and glucose uptake in peripheral tissues and may influence gut microbiota and intestinal glucose absorption. Dihydroberberine has superior oral bioavailability compared to berberine due to better absorption and reduced first-pass metabolism, resulting in higher plasma concentrations of active berberine metabolites. It also modulates GLP-1 secretion and inhibits mitochondrial respiratory complex I, similar to berberine.
Side effects
Preliminary human studies indicate good safety and tolerability of dihydroberberine at doses of 100-200 mg daily. Gastrointestinal discomfort is less frequent than with berberine. Potential drug interactions are similar to berberine, including CYP enzyme modulation; caution is advised with drugs metabolized by CYP3A4 and P-glycoprotein substrates. Due to limited data, standard precautions for berberine derivatives apply. Safety in pregnancy, lactation, children, and severe hepatic or renal impairment has not been established. No significant adverse events have been reported in short-term studies, but uncommon and rare side effects are not well characterized due to limited data.
Dosage
A minimum effective dose of around 100 mg daily of dihydroberberine has been shown to increase plasma berberine levels significantly. Optimal dosage ranges are 100-600 mg daily, often split into multiple doses, achieving comparable or superior effects to 1500 mg daily of berberine. The maximum safe dose has not been definitively established; human studies have used up to 200 mg per dose without adverse effects. Doses should be taken with meals to optimize absorption and reduce gastrointestinal discomfort. Oral capsules are standardized for dihydroberberine content (e.g., GlucoVantage®).
FAQs
Is dihydroberberine safer than berberine?
Early evidence suggests fewer gastrointestinal side effects due to lower required doses and better absorption.
How quickly does it work?
Plasma levels peak around 1 hour post-dose, faster than berberine, but clinical effects on glucose may take longer to manifest.
Can it replace berberine?
Due to superior bioavailability and efficacy at lower doses, dihydroberberine is a promising alternative, but more large-scale clinical trials are needed.
Are there any known drug interactions?
Potential interactions similar to berberine; consult healthcare providers if on medications metabolized by CYP enzymes.
Research Sources
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11171481/ – This randomized, double-blind, placebo-controlled crossover study with 5 healthy young men found that dihydroberberine (100-200 mg) produced significantly higher plasma berberine concentrations compared to 500 mg berberine. The area under the curve was approximately 5 times higher, and the peak concentration was more than 3 times greater. The study also noted a faster Tmax (~1 h vs. 11 h), but no significant glucose or insulin changes were observed, likely due to the short duration and healthy subjects.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8746601/ – This randomized controlled trial on absorption kinetics found that oral dihydroberberine doses (100-200 mg) yielded significantly greater plasma berberine levels than 500 mg berberine in human subjects. Transdermal application in animal models also showed superior bioavailability and glucose homeostasis improvement. The study provides good pharmacokinetic data and preliminary clinical safety information, but is limited by its short-term nature and limited clinical endpoints.
- https://blog.priceplow.com/supplement-research/dihydroberberine-vs-berberine – This article discusses the differences between dihydroberberine and berberine, highlighting dihydroberberine's improved bioavailability and potential benefits for glycemic control. It emphasizes that dihydroberberine achieves higher plasma berberine concentrations at lower doses, making it a more efficient alternative.
- https://blog.priceplow.com/supplement-research/dihydroberberine/glp1-data-resullts – This article explores the potential of dihydroberberine to modulate GLP-1, suggesting a mechanism for improved weight management. It supports the idea that dihydroberberine, as a more bioavailable precursor to berberine, may offer similar metabolic benefits with enhanced efficacy.
- https://shawnwells.com/2025/04/23/natural-glp-1-support/ – This article discusses natural ways to support GLP-1, including the use of dihydroberberine. It suggests that dihydroberberine can be a valuable supplement for metabolic health due to its ability to influence GLP-1 and improve glycemic control.
